Two Sigma Advisers
OVID icon

Two Sigma Advisers’s Ovid Therapeutics OVID Stock Holding History

Two Sigma Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-239,200
Closed -$390K – 1521
2025
Q4 		$390K Buy
239,200
+87,400
+58% +$135K ﹤0.01% 1877
2025
Q3 		$197K Buy
+151,800
New +$132K ﹤0.01% 2139
2023
Q1 		– Sell
-14,000
Closed -$26K – 2715
2022
Q4 		$26K Sell
14,000
-4,300
-23% -$7.33K ﹤0.01% 2413
2022
Q3 		$34K Sell
18,300
-5,500
-23% -$11.5K ﹤0.01% 2404
2022
Q2 		$51K Sell
23,800
-10,600
-31% -$25.6K ﹤0.01% 2480
2022
Q1 		$108K Sell
34,400
-12,700
-27% -$39.9K ﹤0.01% 2494
2021
Q4 		$151K Sell
47,100
-60,900
-56% -$209K ﹤0.01% 2357
2021
Q3 		$363K Sell
108,000
-224,200
-67% -$818K ﹤0.01% 2041
2021
Q2 		$1.3M Buy
332,200
+12,600
+4% +$49.7K ﹤0.01% 1516
2021
Q1 		$1.28M Sell
319,600
-273,800
-46% -$909K ﹤0.01% 1510
2020
Q4 		$1.37M Buy
593,400
+425,200
+253% +$1.98M ﹤0.01% 1430
2020
Q3 		$965K Buy
+168,200
New +$1.13M ﹤0.01% 1513
2020
Q2 		– Sell
-23,400
Closed -$70K – 2577
2020
Q1 		$70K Buy
23,400
+4,200
+22% +$14.2K ﹤0.01% 2348
2019
Q4 		$80K Buy
+19,200
New +$60.6K ﹤0.01% 2267

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers's OVID Position: Q1 2026 in Review

Two Sigma Advisers sold out of Ovid Therapeutics (OVID) in Q1 2026, closing a stake of 239,200 shares — an estimated $390K sold.

Two Sigma Advisers first reported a position in OVID in Q4 2019 and held it in 14 quarters. The position peaked at $1.37M in Q4 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Two Sigma Advisers reported no remaining Ovid Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 239,200 Ovid Therapeutics shares in Q1 2026, an estimated $390K.
  • Two Sigma Advisers first reported a position in Ovid Therapeutics in Q4 2019 and held it in 14 quarters.
  • Two Sigma Advisers's Ovid Therapeutics position peaked at $1.37M in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.